secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001140361-25-030537
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed receives FDA approval for BRINSUPRI (brensocatib), first treatment for NCFB
--------------------------------------------------------------------------------

- FDA approved BRINSUPRI 10 mg and 25 mg for non-CF bronchiectasis in adults and children ≥12 years.
- Phase 3 ASPEN: 21.1% (10 mg) and 19.4% (25 mg) reduction in annual exacerbation rate vs placebo.
- Approximately 500,000 U.S. patients diagnosed with NCFB; first approved therapy for this condition.
- BRINSUPRI available by prescription via specialty pharmacy; commercial launches in EU/UK/Japan expected 2026.
- Insmed to host investor call today at 12:00 PM ET to discuss the approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125030537/0001140361-25-030537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125030537/ef20053490_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-030537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer